Experimental HCV Drugs
Experimental HCV Drugs
PSI-7977 Trial Adds New Regimens
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 14 June 2011 07:48
- Written by Pharmasset
The ELECTRON trial, testing the HCV polymerase inhibitor PSI-7977, has added new arms looking at regimens with shorter duration or no interferon for people with HCV genotypes 1, 2, and 3.
BI201335 Shows Potent Activity against HCV
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 07 June 2011 13:23
- Written by Liz Highleyman
HCV protease inhibitor BI201335 plus pegylated interferon/ribavirin was well-tolerated and demonstrated good activity in treatment-naive and -experienced genotype 1 chronic hepatitis C patients. 
European Committee Recommends Boceprevir (Victrelis)
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 20 May 2011 14:35
- Written by Merck
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of the HCV protease inhibitor boceprevir (brand name Victrelis) for treatment of chronic hepatitis C.
PSI-7977 + BMS-790052 Trial for Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 03 June 2011 13:01
- Written by Pharmasset
Pharmasset announced the start of a Phase 2a study of an all-oral antiviral regimen of HCV polymerase inhibitor PSI-7977 plus NS5A replication complex inhibitor BMS-790052.
BI 201335 for Hepatitis C Moves into Phase 3 Trials
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 28 April 2011 17:58
- Written by Boehringer Ingelheim
Boehringer Ingelheim this week announced that enrollment has begun for a Phase 3 clinical trial of its experimental HCV NS3/4A protease inhibitor BI 201335.
Web Design and Development by